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OBJECTIVES:
 
To study changes in health-related quality
of life (HR-QL) following acute myocardial infarction
(AMI) or congestive heart failure (CHF) in older people
(
 
 
 
57 yr).
 
DESIGN:
 
Prospective cohort study.
 
SETTING: 
 
Primary healthcare registers.
 
PARTICIPANTS:
 
Patients were enrolled on the basis of
primary healthcare records. Eighty-nine AMI patients (mean
age 
 
 
 
 69.5) and 119 CHF patients (mean age 
 
 
 
 74.5)
were included for analysis.
 
MEASUREMENTS:
 
HR-QL was conceptualized and mea-
sured by means of physical (activities of daily living (ADL),
instrumental activities of daily living (IADL)), psychological
(depressive symptoms, anxiety), social, and role functioning.
Premorbid data (T0) were available from a 1993 community-
based survey. Incident AMI and CHF cases, developed after
1993, were prospectively followed for 12 months. Assess-
ments were performed at 6 weeks (T1) and 6 (T2) and 12
months (T3) after diagnosis.
 
RESULTS:
 
At the premorbid assessment, AMI patients did
not significantly differ on HR-QL from a reference group
of older people, whereas CHF patients were on average
older and had worse HR-QL compared to the reference
group. Although CHF had not yet been diagnosed at T0,
symptoms were already present and resulted in decreased
levels of functioning. At T1, all HR-QL measures showed
worse functioning compared with T0, except for depres-
sive symptoms that presented later (at T2). In contrast to
the delay in depressive symptoms, a significant increase in
anxiety was already seen at T1. The effect of the somatic
conditions was the largest on physical functioning. Effects
on psychological and social functioning were less pro-
nounced but still significant. Effects were maintained dur-
ing the 12 months of follow-up.
 
CONCLUSION:
 
The negative consequences on HR-QL
in both AMI and CHF patients are not temporary. No re-
covery of function was seen in AMI patients, and function-
ing of CHF patients continued to decline in the first year
after diagnosis. 
 
J Am Geriatr Soc 49:1052–1058, 2001.
Key words: health-related quality of life; cardiovascular
 
disease; older
 
C
 
ardiovascular diseases, including acute myocardial in-
farction (AMI) and congestive heart failure (CHF),
are a major healthcare problem, especially with an aging
population. Although, AMI is the result of progressive ar-
teriosclerosis, a heart attack often takes patients by sur-
prise. The mortality rate among patients with AMI is high
and increases with age. The 1-year cardiac mortality rate is
12% for persons under age 75 and 18% for persons age
 
75 and older.
 
1
 
 CHF is a pathophysiological disease charac-
terized by the inability of the heart to pump blood at a rate
commensurate with the requirements of the metabolizing
tissues of the body. It is a common illness. The incidence is
still increasing, both because of the aging of the popula-
tion and the higher AMI survival rate. The prognosis for
those with chronic CHF is poor, with a mortality rate as
high as 30% within 1 year of onset of heart failure symp-
toms.
 
2
 
 For those who survive, AMI and CHF may have
considerable impact on functioning and well-being. The
effects of both diseases might be similar, although some
are disease specific. Persons who experience an AMI are
suddenly confronted with a life-threatening event. The first
heart attack comes unannounced and might provoke ini-
tial feelings of fear and despair. By contrast, CHF occurs
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less suddenly. Persons recently diagnosed as having CHF
might have been suffering from dyspnea or fatigue for
months. Although one might not be aware of the cardio-
vascular cause, the diagnosis of CHF generally comes as
less of a shock compared with AMI.
Both AMI and CHF may be disabling diseases and com-
plete functional recovery may be possible. Therefore, ther-
apy serves two primary goals. The first is to prevent further
progression of the disease or mortality and the second is to
alleviate symptoms and suffering. Quantifying these latter
variables requires the use of health-related quality of life
(HR-QL) measures: questionnaires that elicit from patients
the impact of their condition on their functioning, symp-
toms, and quality of life. Over the past decade, there has
been a surge in the measurement of quality of life as an in-
dicator of health outcome. Quality of life has been defined
by the World Health Organization as “an individual’s per-
ception of their position in life, in the context of the culture
and value systems in which they live and in relation to
their goals, expectations, standards and concerns.”
 
3
 
 HR-QL
can be defined on the basis of several different viewpoints.
It is a global construct and its operationalization (method
of measurement) depends on the research question and
study goal. However, many quality of life researchers agree
that HR-QL is a multidimensional construct with at least
three main domains, physical, psychological, and social
functioning or well-being.
The objective of this study is to describe changes in
three domains of HR-QL immediately after diagnosis of
AMI or CHF. The change in quality of life after a car-
diac event has been the subject of several studies,
 
4–6
 
 but
previous studies have several limitations, which this study
has attempted to rectify. First, the present study is longi-
tudinal, which is preferable to cross-sectional designs.
The Medical Outcomes Study (MOS) has great scientific
interest, yet it is limited by its cross-sectional design.
The MOS compares HR-QL for several chronic condi-
tions and shows that patients with AMI and CHF have
the poorest HR-QL when compared with patients with
diabetes mellitus, chronic lung problems, gastrointestinal
disorders, or arthritis.
 
7
 
 Second, community-based data are
preferable to trials including selected patient groups. Few
longitudinal studies on changes in HR-QL in patients with
either AMI or CHF have been performed, and most previ-
ous trials focus on treatment or cardiac rehabilitation
effects.
 
4
 
 These trials reflect the highly selected group of
patients that enter clinical trials. Cross-sectional data or
results from clinical trials are not the first choice when
one is interested in HR-QL following AMI or CHF in
general. Third, most studies focus on one single aspect of
HR-QL (e.g., on psychological well-being or on physical
functioning only). Because HR-QL is a multidimensional
construct, it is preferable to study several domains of HR-
QL, as does the present study. Fourth, we have included
data on AMI and CHF patients. This enables us to com-
pare the patterns of change in HR-QL domains for an
acute (AMI) and a chronic (CHF) heart condition. From a
theoretical point of view, the acute condition, AMI, and
the more chronic condition, CHF, might produce different
patterns of changes in HR-QL domains. It is expected that
physical functioning decreases immediately after the oc-
currence of an AMI and that some recovery takes place in
 
the following months. By contrast, less dramatic changes
are expected in patients with a recent diagnosis of CHF
because this is a more chronic disease.
The focus of this paper is on the effects of AMI or
CHF on physical, psychological, and social functioning in
a sample of older adults, drawn from primary healthcare
registers. The following questions are explored in this
study: To what extent does AMI or CHF affect HR-QL
domains? Are the intensity and timing of changes compa-
rable for the three domains? Is any recovery in HR-QL
seen in the 12 months following diagnosis? The present
study is unique, because we not only examine HR-QL af-
ter AMI and in recently diagnosed CHF patients but also
include data on the premorbid HR-QL status in our analy-
sis. This allows us to compare the situation after AMI or
CHF with the premorbid situation, that is, with a point in
time when patients were not yet suffering from the speci-
fied heart condition.
 
METHODS
 
This study is part of the Groningen Longitudinal Aging
Study (GLAS), a population-based prospective follow-up
study of the determinants of disease, functional disability,
well-being, and utilization of care in older persons.
 
8–12
 
Baseline Participants
 
The study population comprised 8,723 persons age 57 and
older on January 1, 1993, who were registered as patients
with the 27 general practitioners participating in the Morbid-
ity Registration Network Groningen. A total of 152 persons
had died or left the practice by the time the contact was made,
leaving 8,571 eligible persons. Useful baseline data were avail-
able for 5,279 subjects (62% of 8,571 eligible older persons).
The GLAS baseline assessment was carried out in 1993 and
consisted of an interview and a questionnaire sent by mail.
With respect to subject nonresponse bias, nonresponse was
not random but was associated with higher age and with fe-
male gender. Objectives, design, and matters of representa-
tiveness of the GLAS study have been described elsewhere.
 
8,9
 
The results showed no evidence of nonresponse bias relevant
to the issues addressed in our study.
 
Inclusion Criteria
 
From the baseline wave in 1993 until January 1, 1998, the
general practitioners provided the names of all patients with
a new post-baseline episode or diagnosis of AMI or CHF
according to the criteria of the International Classification
of Primary Care (ICPC).
 
13
 
 AMI was diagnosed if two of the
following three findings were present: (1) chest pain charac-
teristic of myocardial ischemia and lasting more than 15
minutes, (2) abnormal ST-T changes or Q waves on an elec-
trocardiogram, or (3) elevation of blood cardiac enzymes
(code K75 of ICPC). For those persons with AMI who did
not present with chest pain, the other two abnormalities
had to be present to allow a diagnosis of AMI. CHF was di-
agnosed if three of the following five clinical manifesta-
tions were present: (1) dependent edema, (2) raised jugular
venous pressure or hepatomegaly in the absence of liver dis-
ease, (3) signs of pulmonary congestion or pleural effusion,
(4) enlarged heart, and (5) dyspnea in the absence of pulmo-
nary disease (code K77 of ICPC). Twenty-eight patients ex-
perienced both a new episode of AMI and first diagnosis of 
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CHF, in 19 cases CHF diagnosis preceded AMI, and in nine
cases AMI occurred before CHF. For these cases, only data
of the first diagnosed episode are included in this study.
 
Assessment Points
 
All outcome variables were assessed on four occasions: at
baseline (T0: premorbid) and 6 weeks (T1), 6 months
(T2), and 12 months (T3) after diagnosis. The premorbid
assessment took place in 1993 for all participants, whereas
the timing of T1, T2, and T3 depended on the time of di-
agnosis and occurred between 1993 and 1998. The mean
length of the time interval between the baseline interview
and the new episode was 27 months for AMI and 26
months for CHF and ranged from 1 to 58 months.
 
Patients
 
During the enrollment period, 207 patients with a new ep-
isode of AMI and 293 patients with a first diagnosis of
CHF after baseline were recruited. Of the 207 persons
with AMI, 49 (24%) died before T1 and 16 were already
participating in one of the other six GLAS cohort studies.
Of the 142 potential responders, 23 refused participation
in the study and 19 did not participate for other reasons,
leaving 100 for T1 (70%). Of these 100 AMI patients who
started the follow-up study, 93 (93%) participated in T2
and 89 (89%) also completed T3. Of the 293 persons with
CHF, 25 (8.5%) died before T1 and 33 were already par-
ticipating in another GLAS cohort study. Of the 235 po-
tential responders, 45 refused participation and 28 did not
participate for other reasons. Of the 162 CHF patients
who started with the follow-up study, 136 (84%) partici-
pated in T2 and 119 (73%) also completed T3. Nonre-
sponse analyses showed that, at baseline (T0), responders
were significantly younger and had better physical func-
tioning scores, on average, than nonresponders.
 
Outcome Measures
 
HR-QL is conceptualized as relating to three domains of
functioning: physical, psychological, and social.
Physical functioning is assessed with the Groningen
Activity Restriction Scale (GARS). GARS comprises 18
ADL (activities of daily living) and IADL (instrumental
activities of daily living) items, each with four response
categories. Scores may range from 18 (no physical dysfunc-
tioning) to 72 (maximum level of dysfunctioning). Exam-
ples of GARS items are “Can you dress yourself without
any help from others?” and “Can you walk up and down
the stairs?” The results of previous studies showed that
GARS meets the stochastic cumulative scalability criteria
of the Mokken Model.
 
14,15
 
Depressive symptomatology and anxiety, indicators of
psychological functioning, were assessed with the Hospital
Anxiety and Depression Scale (HADS).
 
16,17
 
 Items referring
to symptoms that may have a physical cause (e.g., insom-
nia and weight loss) are not included in the scale. There-
fore, HADS is considered to have no bias towards depres-
sive symptoms resulting from concurrent general medical
conditions.
 
17
 
 Examples of items are “I still enjoy the things
I used to enjoy.” “I feel as if I am slowed down.” Both
subscales consist of seven items and the theoretical ranges
vary from 0 to 21; higher scores indicate more symptoms.
HADS has been validated for an older Dutch population.
 
17
 
Social functioning is assessed with two MOS sub-
scales: MOS social functioning and MOS role function-
ing.
 
18
 
 The social functioning subscale measures the extent
to which health interferes with normal social activities
such as visiting friends in a one-item question. The role
functioning subscale measures the extent to which health
interferes with usual daily activities such as housework or
paid work. Both scales range from 0 to 100. Scores are re-
versed so that higher scores indicate poorer functioning,
corresponding with scores on physical and psychological
functioning. The psychometric properties of the Dutch ver-
sion of the MOS scales were approved in a pilot study.
 
19
 
Analysis
 
Baseline characteristics of patients were compared with a
reference group (i.e., all the GLAS baseline participants
except those who developed AMI or CHF), to study any
differences in HR-QL at baseline (adjusted for age, gender,
and marital status differences). Changes in the three HR-
QL domains are presented in graphs showing the means
and 95% confidence intervals (CI) at each assessment
point. Changes between two assessment times are tested
for statistical significance with paired sample 
 
t
 
-tests and
the magnitude of changes is quantified by calculating ef-
fect sizes using Cohen’s method.
 
20
 
 Effect sizes are calcu-
lated by dividing the mean change over a period by the
standard deviation (SD) of that change. An effect size of
.20 indicates a small effect, an effect size of .50 a medium
effect and .80 indicates a large effect.
 
20
 
 In addition, analy-
sis on individual patient level was included by calculating
the percentage of patients with a substantial deterioration
in HR-QL. The definition of this change was deduced
from Cohen’s effect sizes. According to Cohen, an effect
size 
 
 
 
.80 indicates a large change, which corresponds to a
change of at least 0.8 
 
 
 
 SD. A large change, for each pe-
riod, was defined as a change larger than 0.8 
 
 
 
 SD (i.e.,
the SD of the change between T0 and T1).
 
RESULTS
Patient Characteristics
 
Table 1 shows the premorbid characteristics of the patient
groups and a reference group. Data on premorbid charac-
teristics were collected during the same period and in the
same study for all groups. The reference group consisted
of 4,802 GLAS participants who did not develop AMI or
CHF between 1993 and 1998. Compared with the refer-
ence group, the percentage of female AMI patients was
low, whereas CHF patients were significantly older and
more often lived without a partner. Comparisons of pre-
morbid HR-QL scores were adjusted for these differences
in age, gender, and marital status. There were no signifi-
cant differences in premorbid HR-QL between AMI pa-
tients and the reference group, but CHF patients had more
depressive symptoms and poorer social functioning and
role functioning compared with the reference group (
 
P
 
 
 
 
 
.05) (see Table 1). Unadjusted premorbid physical func-
tioning in CHF patients was significantly worse compared
with the AMI or reference groups but was not statistically
significant after adjusting for age, gender, and marital sta-
tus. Comparisons of psychological and social functioning
in the AMI and CHF groups showed slightly poorer psy- 
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chosocial functioning in the CHF group, but the adjusted
(premorbid) differences were not statistically significant.
 
Physical Functioning
 
Figure 1 shows the change in physical functioning, expressed
as GARS score, in AMI and CHF patients. In AMI pa-
tients, mean physical functioning during follow-up changed
from 22.0 (T0) to 25.9 (T1), 25.4 (T2), 25.8 (T3) and in
CHF patients from 25.7 to 30.7, 32.1, 32.1, respectively. Six
weeks after diagnosis (T1), physical functioning was worse
for both cohorts in comparison with premorbid levels. Six
and 12 months after diagnosis (T2 and T3), the level of
physical functioning remained worse and did not return to
premorbid levels. The change in physical functioning from
premorbid to 6 weeks after diagnosis (T0–T1) was statisti-
cally significant in both patients groups, and for CHF pa-
tients the mean change between T1 and T3 was also signif-
icant (paired sample 
 
t
 
-test 
 
P
 
 
 
 
 
 .05, see Table 2).
 
Psychological Functioning
 
In AMI patients, mean levels of anxiety changed from 3.8
(T0) to 5.3 (T1), 5.1 (T2), 5.1 (T3) and in CHF patients from
3.9 to 4.6, 4.6, 5.2, respectively. Patients who developed
AMI or CHF reported significantly higher levels of anxiety
after diagnosis compared with premorbid data (see also Ta-
ble 2). After 12 months, mean levels of anxiety were still ele-
vated compared with premorbid levels. Just after diagnosis,
patients did not seem to experience higher levels of depressive
symptoms, but 6 and 12 months later an increase in depres-
sive symptoms was observed in both patients groups. Mean
levels of depressive symptoms were 4.45, 4.5, 5.4, and 5.4 in
AMI and 5.6, 5.4, 6.0, and 6.1 in CHF patients, respectively.
 
Social and Role Functioning
 
In AMI patients, mean social functioning changed from
19.1 (T0) to 35.0, 32.2, and 31.3 and mean role function-
ing changed from 26.1 to 53.4, 48.2, and 46.4. In CHF
patients means were 29.4, 41.7, 35.7, and 39.8 for social
functioning and 46.2, 54.8, 58.7, and 63.5 for role func-
tioning, respectively. Both social functioning and role func-
tioning worsened significantly 6 weeks after diagnosis (see
also Table 2). The onset effect (T0–T1) on role functioning
was more pronounced in the AMI group than in the CHF
group, whereas the decline in role functioning between T1
and T3 was significant only for CHF patients. Social func-
 
Table 1. Characteristics of a Reference Group and Premorbid Characteristics of AMI, CHF Patients
 
*
 
Parameter
Reference group
(n 
 
 
 
 4,802)
%
AMI
(n 
 
 
 
 89)
%
CHF
(n 
 
 
 
 119)
%
Females 57 34
 
†
 
59
Without partner 32 27 45
 
†
 
Educational level
Low 3 4 3
Moderate 86 87 87
High 11 9 10
Mean (SD) Mean Adj.
 
‡
 
(SD) Mean Adj.
 
‡
 
(SD)
Age (yrs) 69.2 (7.9) 68.5 — (7.2) 74.5
 
†
 
— (7.2)
Physical functioning 22.8 (7.9) 22.0 22.5 (5.6) 25.7
 
†
 
23.8 (9.0)
Anxiety 3.9 (3.6) 3.8 4.1 (3.8) 3.9 4.0 (3.6)
Depressive symptoms 4.3 (3.5) 4.5 4.6 (3.5) 5.6
 
†
 
5.3
 
§
 
(4.0)
Social functioning 18.2 (25.2) 19.1 20.6 (24.6) 29.4
 
†
 
25.1
 
§
 
(30.0)
Role functioning 24.9 (40.6) 26.1 28.4 (40.1) 46.2
 
†
 
39.9
 
§
 
(47.4)
 
*
 
The reference group includes the baseline participants of the GLAS study minus the 477 patients who developed AMI or CHF between 1993 and 1998. On all HR-QL
measures, higher scores indicate poorer functioning.
 
†
 
Statistically significant difference with reference group (
 
P
 
 
 
 
 
 .05, unadjusted).
 
‡
 
Adjusted means are adjusted for age, gender, and marital status, according to distributions in reference group.
 
§
 
Statistically significant difference between adjusted means in CHF and reference group (
 
P
 
 
 
 
 
 .05). Differences in adjusted means between AMI and reference group, and
between AMI and CHF group were not statistically significant.
AMI 
 
 
 
 acute myocardial infarction; CHF 
 
 
 
 congestive heart failure; SD 
 
 
 
 standard deviation; HR-QL 
 
 
 
 health-related quality of life; GLAS 
 
 
 
 Groningen Longitudinal
Aging Study.
Figure 1. Change in physical functioning after AMI or CHF. 
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tioning and role functioning did not return to premorbid lev-
els after 6 or 12 months but remained worse than T0 levels.
 
Effect Sizes
 
The changes between T0 and T1, T1 and T3, and T0 and
T3 and their effect sizes are summarized in Table 2. The
changes between T2 and T3 are rather small and T2 assess-
ments are not included in the table for reasons of compre-
hensiveness. The change between T0 and T1 represents the
difference between premorbid functioning and functioning
immediately after diagnosis (the onset effect). The largest
effect sizes, both for AMI and CHF patients, were found
for physical functioning (ES 
 
 
 
 .70 and .71, respectively). A
moderate onset effect was found for anxiety. The onset ef-
fect for anxiety was more pronounced in AMI patients
than in CHF patients (ES 
 
 
 
 .34 in AMI and .20 in CHF pa-
tients). No obvious onset effects for depressive symptoms
were found (ES 
 
 
 
 .20). As for social functioning, small ef-
fect sizes were found in both AMI and CHF patients,
whereas an onset effect for role functioning was found only
in AMI patients (ES 
 
 
 
 .53) and was minimally measurable
in CHF patients (ES 
 
 
 
 .19). Comparing the onset effects of
AMI and CHF on HR-QL aspects showed comparable ef-
fects for both diseases, with the exception of the effect on
role functioning, which was more pronounced after AMI
than after CHF. This also held to a lesser extent for anxi-
ety. The baseline situation (T0) of CHF patients was al-
ready worse on several HR-QL domains compared with
the reference group or the AMI group but, nevertheless,
worsened further after diagnosis.
Table 2 also shows the changes and their effect sizes
between T1 and T3 (the difference between functioning 6
weeks after diagnosis and 1 year later (i.e., illness course
effect)). Interestingly, HR-QL of patients with AMI or
CHF did not change much in the year following diagnosis,
compared with the change in HR-QL directly after diag-
nosis. Illness course effect sizes did not exceed .28, indicat-
ing nonsignificant or small effect sizes. However, two
things are worth mentioning. First, although no onset ef-
fect (T0–T1) for depressive symptoms was seen, an in-
crease in depressive symptomatology was observed in the
year following diagnosis (T1–T3). In both AMI and CHF
patients, the effect size was small but evident (ES 
 
 
 
 .20).
Second, physical functioning and role functioning declined
slightly (ES 
 
 
 
 .20) in patients with CHF, whereas no T1–
T3 effect was measured in AMI patients.
The lower section of Table 2 shows the total effect
over time of AMI or CHF, comparing functioning after 1
year with the premorbid situation (T0–T3). These data in-
dicate a large effect for physical functioning, which was
more pronounced in CHF patients (ES 
 
 
 
 .90) than in AMI
patients (ES 
 
 
 
 .68). In comparison with premorbid data,
medium effects for anxiety, social functioning, and role
functioning were found (.20 
 
 
 
 ES 
 
 
 
 .50). The total effect
over time for depressive symptoms was small in AMI (ES 
 
 
 
.24) and not evident in CHF patients (ES 
 
 
 
 .11).
Changes at the individual patient level are also presented
in Table 2, to contrast with changes at the group level as dis-
cussed above. These results show large differences between
patients. Consecutively, we present the percentage of patients
 
Table 2. Change in HR-QL Parameters in Patients with AMI or CHF
 
AMI (n 
 
 
 
 89) CHF (n 
 
 
 
 119)
Mean
change* ES*
% of patients
with substantial
deterioration
 
†
 
Mean 
change* ES*
% of patients
with substantial
deterioration
 
†
 
Onset effect (T0–T1)
Physical 3.9
 
‡
 
.70 43 5.0
 
‡
 
.71 41
Anxiety 1.5
 
‡
 
.34 32 0.7
 
‡
 
.20 30
Depressive symptoms 0.1 .01 20
 
 
 
0.2 .06 19
Social 15.9
 
‡
 
.42 39 12.3
 
‡
 
.39 24
Role 27.3
 
‡
 
.53 44 8.6
 
‡
 
.19 23
Illness course effect (T1–T3)
Physical
 
 
 
0.1
 
 
 
.06 10 1.4
 
‡
 
.28 24
Anxiety
 
 
 
0.2
 
 
 
.02 18 0.6
 
‡
 
.19 25
Depressive symptoms 0.9
 
‡
 
.25 29 0.7
 
‡
 
.22 22
Social  3.7  .11 13  1.9  .07 11
Role  7.0  .16 20 8.7‡ .22 23
Total effect over time (T0–T3)
Physical 3.8‡ .68 54 6.4‡ .90 52
Anxiety 1.3‡ .35 29 1.3‡ .32 35
Depressive symptoms 0.9‡ .24 29 0.5 .11 31
Social 12.1‡ .42 26 10.4‡ .37 19
Role 20.3‡ .41 35 17.3‡ .37 31
*Positive changes and effect sizes (ES) indicated deteriorating functioning for all parameters.
†Patients with a deterioration of at least 0.8   SD were counted. The SD of changes between T0 and T1 was comparable in both groups. This resulted in the following cut-off
points: change in physical functioning  5; change in anxiety  3; change in depressive symptoms  3; change in social functioning  40; and change in role functioning  50.
‡Statistically significant change, i.e., paired sample t-test P   .05.
AMI   acute myocardial infarction; CHF   congestive heart failure; SD   standard deviation.JAGS AUGUST 2001–VOL. 49, NO. 8 CHANGES IN HR-QL IN OLDER PATIENTS WITH AMI OR CHF 1057
whose HR-QL deteriorated by at least 0.8   SD. About half
or more of the patients did not change more than 0.8   SD
and were categorized as “relatively stable” patients. A minor-
ity of patients showed an improvement on HR-QL aspects
following AMI or CHF. As many as 19% to 54% of patients
showed a deterioration in HR-QL aspects between T0 and
T3. Some differences between AMI and CHF patients were
noticed. For CHF patients, the impact on physical function-
ing was most pronounced. Between T0 and T3, as many as
52% of the CHF patients reported a deterioration in physical
functioning. Baseline scores indicated that this group had
poorer physical functioning to begin with, but it became even
worse. The onset effect (between T0 and T1) on role func-
tioning was more pronounced in AMI patients than in CHF
patients (44% and 23% of patients, respectively, reported a
deterioration in functioning, P   .003).
DISCUSSION
The present study focuses on changes in three domains of
HR-QL following a diagnosis of AMI or CHF. Large ef-
fects, measured on the basis of effect size, were seen for
physical functioning in both patient groups. This is not
surprising because both cardiovascular diseases are known
for their large somatic consequences.
Physical functioning, measured with GARS, declined
immediately after diagnosis and deteriorated even further
in CHF patients in the following 12 months. At 6 weeks,
follow-up mean scores for physical functioning had in-
creased from 22 (premorbid) to 26 in AMI patients and
from 26 to 31 in CHF patients. This increase of 4 and 5
points, respectively, indicates that on average patients ex-
perienced slightly more problems in 4 or 5 of the 18 activ-
ities, or a lot more problems in at least two activities.
Comparing the means with other patient groups shows
that the physical functioning of CHF patients is on aver-
age as poor as that of patients who have had rheumatoid
arthritis for at most 4 years (mean scores 32.5).21
Effects on psychological and social functioning were
less pronounced, but nevertheless significant. In both pa-
tient groups, an increase in anxiety was observed immedi-
ately after diagnosis, whereas an increase in depressive
symptoms specifically was observed at 6 months. The first
psychological reaction to AMI and CHF is expressed as
anxiety, whereas depressive symptoms develop at a later
stage. Compared with premorbid levels, 29% of AMI pa-
tients showed a substantial increase in depressive symp-
toms at 12 months ( 0.8   SD), compared with 31% of
CHF patients. Often psychological disturbance, particu-
larly depression, in the presence of physical illness is re-
garded as understandable and therefore not of great clini-
cal importance. This is an erroneous conclusion, because
there is substantial evidence that untreated psychological
comorbidity contributes significantly to overall morbidity,
mortality, and cost of health care.22 Feelings of anxiety
and depression at 1-year follow-up were higher than pre-
morbid levels. Premorbid data in the CHF group showed
a relatively high level of depressive symptoms compared
with AMI patients and the reference group, even after ad-
justment for age differences. A possible explanation for
this finding might be that CHF is not a sudden event;
symptoms of cardiac dysfunctioning might have been
present for some time. Clearly, premorbid HR-QL aspects
of AMI patients were not different from the reference
group, whereas CHF patients already had a poorer HR-
QL on all aspects except feelings of anxiety.
Most studies reporting on change in HR-QL in AMI
or CHF patients were part of a clinical trial comparing
treatments or rehabilitation programs. As a consequence,
most of these studies included patients selected from the
hospital. However, it is common knowledge that patients
who participate in trials are a select group likely to be free
of major comorbidity. Changes measured in these patients
might differ from changes in a more community-based
sample. The present study can be considered community-
based. Patients were not selected from hospital records, as
in most studies, but from general practitioners’ primary
healthcare records. Because 99% of the Dutch population
is registered in a primary care setting and most patients will
contact their primary care physician in the event of AMI or
CHF, this study may be considered community based.
Limitations of the Study
An important advantage of the present study is the com-
parison with premorbid conditions. However, a few re-
marks should be made concerning this point. First of all,
premorbid data were collected in 1993 during a population
survey. Incident cases of AMI and CHF were included in
the study from 1993 to 1998. The timing of the three fol-
low-up measurements depended on the time of diagnosis.
As a consequence, the period between the premorbid mea-
surement and T1 ranged from 1 month up to 58 months,
averaging 27 months for the AMI group and 26 months for
the CHF group. The difference in functioning between T0
and T1 is therefore not only due to AMI or CHF. The effects
of aging and other morbidity might also be of influence. As
the period between T0 and T1 increased, the influence of
aging and other morbidity might also have increased. Some
caution is needed when interpreting the changes in HR-QL
as being solely due to AMI and CHF.
In our study, nonresponse could occur at three phases:
before the baseline assessment, after diagnosis (before T1),
and during follow-up. Although careful nonresponse anal-
yses are performed, a response bias cannot be excluded.
The nonresponse analyses showed that the study partici-
pants were younger, more often male, and had better base-
line physical functioning and less comorbidity compared
with nonresponders. Even in these somewhat less severely
limited patients, effects on HR-QL were substantial; the ef-
fects might even be larger for the total patient population.
Our study does not include longitudinal data of the
reference group, which may show changes in HR-QL irre-
spective of AMI and CHF. Because a population age 57
and older was followed longitudinally, aging effects might
also have influenced changes in HR-QL. In the baseline
reference group, aging was significantly correlated with a
decline in HR-QL. A positive linear association was found
for depressive symptoms and age. Quadratic associations
were seen for other aspects of HR-QL, showing larger ef-
fects for the higher age groups. The mean age of CHF pa-
tients was 6 years higher than of AMI patients; therefore
aging might have influenced results for the CHF group
particularly. For the reference group, we calculated the
mean aging effect for persons age 75 years (i.e., CHF
group). We found that, per year, these individuals’ physi-1058 VAN JAARSVELD ET AL. AUGUST 2001–VOL. 49, NO. 8 JAGS
cal functioning deteriorated by a score of 0.5; deteriora-
tion was less than 0.1 for anxiety and depression, 1.0 for
social functioning, and 2.0 for role functioning. The ef-
fects of AMI and CHF were much larger; therefore we
concluded that aging effects, although present, were of mi-
nor importance to the results.
Implications of the Study
The data clearly suggest that the negative consequences of
both AMI and CHF are not temporary. Immediately after
diagnosis, poorer HR-QL was observed, and no significant
improvement was measured in the 12 months after the
diagnosis on any of the HR-QL variables for both groups.
For CHF, a chronic debilitating illness, it is understandable
that functioning remains affected in the long-term. How-
ever, it was striking that HR-QL in CHF patients continued
to deteriorate over the course of the follow-up. For AMI,
we expected the onset effect on HR-QL to be large, followed
by some improvement after a number of months. However,
the results showed no improvement in HR-QL during fol-
low-up. Especially when small changes during the 12 months
of follow-up were compared with the premorbid situation, it
was obvious that these improvements were only minimal.
Our results underscore that the consequences of AMI
and CHF are multidimensional and suggest that the multi-
dimensional aspects should be included in treatment. In
addition, the impact on HR-QL is somewhat different for
AMI and CHF. In particular, the impact in CHF patients
is more severe. The observation that the first psychological
reaction to AMI and CHF is expressed as anxiety, whereas
depressive symptoms develop at a later stage is important
for clinical practice.
REFERENCES
1. Aronow WS. Management of older persons after myocardial infarction. J Am
Geriatr Soc 1998;46:1459–1468.
2. Mosterd A. Epidemiology of heart failure [dissertation]. Rotterdam: Erasmus
University of Rotterdam, 1997.
3. WHOQOL group. Study protocol for the World Health Organization
project to develop a quality of life assessment instrument (WHOQOL). Qual
Life Res 1993;2:153–159.
4. Mayou R, Blackwood R, Bryant B et al. Cardiac failure: Symptoms and func-
tional status. J Psychosom Res 1991;35:399–407.
5. Trcieniecka-Green A, Steptoe A. Stress management in cardiac patients: A
premiliminary study of the predictors of improvement in quality of life. J Psy-
chosom Res 1994;38:267–280.
6. Wiklund I, Herlitz J, Hjalmarson A. Quality of life five years after myocar-
dial infarction. Eur Heart J 1989;10:464–472.
7. Stewart AL, Greenfield S, Hays RD et al. Functional status and well-being of
patients with chronic conditions: Results from the Medical Outcomes Study.
JAMA 1989;262:907–913.
8. Kempen GIJM, Jelicic M, Ormel J. Personality, chronic medical morbidity,
and health-related quality of life among older persons. Health Psychol 1997;
16:539–546.
9. Kempen GIJM, Ormel J, Brilman EI et al. Adaptive responses among Dutch
elderly: The impact of eight chronic medical conditions on health-related
quality of life. Am J Public Health 1997;87:38–44.
10. Kempen GIJM, Miedema I, van den Bos GAM et al. Relationship of domain-
specific measures of health to perceived overall health among older subjects.
J Clin Epidemiol 1998;51:11–18.
11. Ormel J, Kempen GIJM, Penninx BWJH et al. Chronic medical conditions
and mental health in old people: Disability and psychosocial resources medi-
ate specific mental health effects. Psychol Med 1997;27:1065-1077.
12. Ormel J, Kempen GIJM, Deeg DJH et al. Functioning, well-being, and health
perception in late middle-aged and older people: Comparing the effects of de-
pressive symptoms and chronic medical conditions. J Am Geriatr Soc 1998;
46:39–48.
13. Lamberts H, Wood M. International Classification of Primary Care. Oxford:
Oxford University Press, 1987.
14. Kempen GIJM, Miedema I, Ormel J et al. The assessment of disability with
the Groningen Activity Restriction Scale—Conceptual framework and psy-
chometric properties. Soc Sci Med 1996;43:1601–1610.
15. Kempen GIJM, Suurmeijer TPBM. The development of a hierarchical poly-
chotomous ADL-IADL scale for noninstitutionalized elders. Gerontologist
1990;30:497–502.
16. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psy-
chiatr Scand 1983;67:361–370.
17. Spinhoven P, Ormel J, Sloekers PPA et al. A validation study of the Hospital
and Depression Scale (HADS) in different groups of Dutch subjects. Psychol
Med 1997;27:363–370.
18. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey:
Reliability and validity in a patient population. Med Care 1988;26:724–735.
19. Kempen GIJM. Het meten van de gezondheidstoestand van ouderen; een toe-
passing van een Nederlandse versie van de MOS-schaal. Tijdschrift voor Ger-
ontologie en Geriatrie 1992;23:132–140.
20. Cohen J. A power primer. Psychol Bull 1992;112:155–159.
21. Doeglas D, Krol B, Guillemin F et al. The assessment of functional status in
rheumatoid arthritis: A cross cultural, longitudinal comparison of the Health
Assessment Questionnaire and the Groningen Activity Restriction Scale. J
Rheumatol 1995;22:1834–1843.
22. Clarke DM. Psychological factors in illness and recovery. NZ Med J 1998;
111:410–412.